No Data
Tianxin Pharmaceutical (603235.SH): The company did not implement share buybacks in December.
On January 2, Gelonghui reported that Tianxin Pharmaceutical (603235.SH) announced that in December 2024, the company did not implement any stock repurchase. As of December 31, 2024, the company has cumulatively repurchased 2,609,720 shares, accounting for 0.5961% of the company's total share capital, with the highest repurchase price at 28.00 yuan/share, the lowest price at 19.17 yuan/share, and the total amount paid was 60,001,880.46 yuan (excluding transaction fees).
The demand for vitamins has recovered year-on-year. Tianxin Pharmaceutical states that the changes in supply and demand have led to an increase in the price of folic acid | Direct coverage of the earnings conference.
① Yu Xiaobing, general manager of Tianxin Pharmaceutical, said that demand in the vitamin market showed signs of a year-on-year recovery in the second half of this year, and changes in market supply and demand caused folic acid prices to rise; ② Dong Yi, director of Tianxin Pharmaceutical, answered questions about the fund-raising project.
A-share pharmaceutical stocks fell, hebei changshan biochemical pharmaceutical dropped over 5%.
On November 22, Gelunhui: Tianxin Pharmaceutical, Zhejiang Shapuaisi Pharmaceutical, Shenzhen Chipscreen Biosciences, Hebei Changshan Biochemical Pharmaceutical fell more than 5%, fujian cosunter pharmaceutical, haisco pharmaceutical group, and China Resources Double-Crane Pharmaceutical followed suit.
Express News | This week, a total of 7 listed companies announced that the company or related parties have been investigated. The next day after the announcement, shenzhen zqgame plummeted by more than 17%.
Express News | Tianshin Pharmaceutical: The actual controller of the company, the chairman, has been placed under detention.
Tianxin Pharmaceutical (603235): Prices of VB1 and VB6 have increased significantly, leading to improved profitability.
Report Overview The company released the third quarter report of 2024, achieving revenue of 1.614 billion yuan, an 8.49% year-on-year increase; net income attributable to parent company of 0.494 billion yuan, a 19.76% year-on-year increase; non-net income attributable to parent company of 0.468 billion yuan, year-on-year.
No Data